Insulin glargine and lixisenatide and Polatuzumab Vedotin-piiq
Determining the interaction of Insulin glargine and lixisenatide and Polatuzumab Vedotin-piiq and the possibility of their joint administration.
No interaction was detected between the selected drugs or effects of joint drug administration are currently understudied, and it takes time and accumulated statistics to determine their interaction. A doctor should be consulted to address the issue of joint drug administration.
Generic Name: insulin glargine / lixisenatide
Brand name: Soliqua 100/33
Synonyms: Insulin Glargine and Lixisenatide
Generic Name: polatuzumab vedotin
Brand name: Polivy
Synonyms: Polatuzumab vedotin, Polatuzumab Vedotin
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Insulin glargine and lixisenatide-Polio vaccine, inactivated
- Insulin glargine and lixisenatide-Poliovirus Vaccine (Inactivated)
- Insulin glargine and lixisenatide-Poliovirus vaccine, inactivated Injection
- Insulin glargine and lixisenatide-Polivy
- Insulin glargine and lixisenatide-Polmon
- Insulin glargine and lixisenatide-Polocaine
- Polatuzumab Vedotin-piiq-Insulin glargine and lixisenatide Subcutaneous
- Polatuzumab Vedotin-piiq-Insulin glargine, recombinant Subcutaneous
- Polatuzumab Vedotin-piiq-Insulin glulisine
- Polatuzumab Vedotin-piiq-Insulin Glulisine (Cartridges and Pens)
- Polatuzumab Vedotin-piiq-Insulin Glulisine (Vials)
- Polatuzumab Vedotin-piiq-Insulin glulisine Subcutaneous